The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

@article{Schey2010TheAO,
  title={The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.},
  author={Stephen A. Schey and Gareth J Morgan and Karthik Ramasamy and Beth Hazel and Dariusz Ladon and Sophie Corderoy and Matthew Jenner and Karen J Phekoo and Kevin Michael Boyd and Faith Davies},
  journal={British journal of haematology},
  year={2010},
  volume={150 3},
  pages={
          326-33
        }
}
We report the results of a Phase I/II dose escalation study to determine the maximum tolerated dose (MTD) of cyclophosphamide when combined with lenalidomide and dexamethasone in relapsed/refractory myeloma. Thirty-one patients were enrolled in cohorts of 3, at five dose levels of cyclophosphamide to a maximum of 700 mg on days 1 and 8 of a 28-d cycle. Patients received lenalidomide 25 mg days 1-21 and dexamethasone 20 mg orally days 1-4 and 8-11. The MTD was 600 mg cyclophosphamide, days 1 and… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Lenalidomide for the treatment of relapsed and refractory multiple myeloma

  • Cancer management and research
  • 2012
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Phase I-II

Chen, Vishal Kukreti, Joseph R. Mikhael, Suzanne Trudel
  • 2009

methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (CVAMP) as induction treatment followed by autografting in previously untreated myeloma

D. Reece, K. W. Song, +10 authors N. J. Bahlis
  • Br J Haematol,
  • 2009

Similar Papers

Loading similar papers…